Last month, the National Health Service (NHS) in Scotland rejected an innovative drug for migraines.
This is in the recommendation from the National Institute for Health and Care Excellence (NICE) which is the body that approves new drugs for NHS.
Unfortunately, Erenumab (a.k.a Aimovig) or the life-changing drug will not be available in the countries that are under NHS including Scotland and the United Kingdom.
One of the reasons why NICE doesn’t approve this drug is because of their doubts about its costs and effectiveness.
They don’t think that this medicine is not worth the money. Even though some people are already claiming it to be an effective preventive drug for migraines.
The innovative drug for migraine works by blocking the calcitonin gene-related peptide receptor (CGRP-R) which is believed that it is vital in treating the mental illness.
However, NICE doesn’t want to risk it because there is not enough evidence to prove its claim.
They said that this medicine may not have a long-term effect unlike other NHS approved drugs for migraines like the Botox.
Therefore, some of the migraine patients who have tried this innovative drug are very disappointed with this news.
They firmly believed that Erenumab is indeed effective in treating their migraines. That’s why they can’t understand why the NHS has rejected it.